Cancer Family
Thoracic Neoplasm
CI-CAN-00000054Explore in graph →
Non-malignant2,893 active trials51 approved drugs626 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000054Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06165874 | [68Ga]Ga-NOTA-RW102 PET Imaging in the Diagnosis of PD-L1-expressing Lung Cancer | unknown | N/A | 20 | Huashan HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT04636775 | Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC) | unknown | — | 46 | Jun Zhang, MD, PhDOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT05599386 |
| Predictors of Acute and Persistent Postoperative Pain in Lung Cancer Surgery |
| unknown |
| — |
| 100 |
| Jannie Bisgaard StæhrOTHER |
| 1 |
| Dec 8, 2023 |
| clinicaltrials |
| NCT02871856 | International Lung Screen Trial (ILST)(ILST) | unknown | N/A | 2,000 | The University of QueenslandOTHER | 2 | Dec 5, 2023 | clinicaltrials |
| NCT04985851 | To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS. | unknown | N/A | 90 | Shanghai Chest HospitalOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT04632758 | Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 3 | 292 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05329025 | A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05669105 | Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research | unknown | — | 200 | Sanguine BiosciencesINDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06143735 | A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors | unknown | Phase 2 | 99 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT00591552 | Use of Harmonic Scalpel to Decrease Lymphatic and Chest Tube Drainage After Lymph Node Dissection With Lobectomy. | unknown | N/A | 50 | Sentara Cardiovascular Research InstituteOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT03600649 | Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas | unknown | Phase 1 | 50 | Salarius Pharmaceuticals, LLCINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT05715996 | Application of Mixed Reality Technique for Percutaneous Lung Nodule Localization: A Prospective, Randomized, Controlled Trial(MR) | unknown | N/A | 74 | Shanghai Chest HospitalOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT04253145 | Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. | unknown | Phase 1 / Phase 2 | 184 | Fundacion OncosurNETWORK | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05291403 | Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined Standard First-line Treatment of Advanced Non-small Cell Lung Cancer and Malignant Pleural Effusion | unknown | N/A | 141 | Qianfoshan HospitalOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05812534 | Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases(CBC) | unknown | Phase 2 | 36 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06016881 | Postoperative Chronic Operation-related Symptoms After Minimally Invasive Lung Surgery | unknown | — | 500 | Fujian Medical University Union HospitalOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06136910 | Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06140082 | Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression | unknown | — | 477 | LI YANOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT04870853 | Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy | unknown | — | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT05311709 | Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities(SOLUCOM) | unknown | Phase 2 | 100 | Vestre Viken Hospital TrustOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT05673590 | Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 612 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT04467801 | Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy(Ipat-Lung) | unknown | Phase 2 | 60 | Jun Zhang, MD, PhDOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05863325 | A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 80 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | unknown | Phase 1 / Phase 2 | 172 | OncoResponse, Inc.INDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06110663 | A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy | unknown | Phase 3 | 314 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Nov 1, 2023 | clinicaltrials |
| NCT05455840 | A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Anterior Mediastinal Disease | unknown | N/A | 15 | Chang Gung Memorial HospitalOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06108726 | A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer | unknown | Phase 2 | 16 | Northern Jiangsu People's HospitalOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06107894 | TIL Therapy for Patients With Advanced Solid Tumors | unknown | Phase 1 | 12 | NeogenTCINDUSTRY | 0 | Oct 30, 2023 | clinicaltrials |
| NCT06104709 | Local and Peripheral Immune Responsive Landscape Induced by Local Cryoablation in Patients With Lung Adenocarcinoma | unknown | — | 10 | China-Japan Friendship HospitalOTHER | 0 | Oct 27, 2023 | clinicaltrials |
| NCT05321615 | Feasibility and Safety of a Wireless Palpator(Palpator) | unknown | N/A | 22 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 0 | Oct 25, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT05259319 | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)(IMMUNOs-SBRT) | unknown | Phase 1 | 92 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06086327 | Application of 68Ga-Pentixafor PET/CT for Thymoma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06086574 | Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer(VIGILANCE) | unknown | — | 80 | University of ManchesterOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06086587 | Development and Application of Molecular Evaluation Instrument for Lung Cancer Diagnosis and Treatment | unknown | — | 500 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Oct 17, 2023 | clinicaltrials |
| NCT06081270 | Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer(MUT-ONC) | unknown | — | 20 | University of Milano BicoccaOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06081777 | Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer(MRDinS3LC) | unknown | — | 65 | Peking University Cancer Hospital & InstituteOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT04737382 | Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.(OSIRIS) | unknown | N/A | 200 | The Netherlands Cancer InstituteOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06065592 | Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms(CAT_PB) | unknown | Phase 1 | 500 | Lebanese UniversityOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06068088 | Dietary Practices and Locally Advanced Lung Cancer (LUNGDIET)(LUNGDIET) | unknown | — | 120 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 5, 2023 | clinicaltrials |
| NCT06065813 | Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer | unknown | Phase 2 | 20 | Northern Jiangsu People's HospitalOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT04591431 | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy(ROME) | unknown | Phase 2 | 400 | Fondazione per la Medicina PersonalizzataOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT05451173 | Combining ICI With SBRT or HypoFrx-RT for ES NSCLC | unknown | Phase 1 / Phase 2 | 83 | Alexander ChiOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04726215 | Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer | unknown | Phase 2 | 50 | CellSight Technologies, Inc.INDUSTRY | 1 | Sep 29, 2023 | clinicaltrials |
| NCT05273047 | RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC(LungKG12Ci) | unknown | — | 458 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT05497973 | Psychosocial eHealth in Advanced Lung Cancer | unknown | N/A | 152 | Institut Català d'OncologiaOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT06060964 | Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management(Breathe Easier) | unknown | Early Phase 1 | 24 | University of South CarolinaOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT04074993 | Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays | unknown | Phase 2 | 35 | JI-YOUN HANOTHER_GOV | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04364776 | Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC. | unknown | — | 100 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05128630 | Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.(DEDALUS) | unknown | Phase 2 | 45 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Dec 12, 2023source: clinicaltrials